Atossa Therapeutics, Inc.
ATOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | -0.26 | -0.15 | 0.10 |
| FCF Yield | -17.71% | -18.89% | -30.97% | -8.81% |
| EV / EBITDA | -1.73 | -0.72 | 1.58 | -2.48 |
| Quality | ||||
| ROIC | -38.64% | -34.47% | -23.47% | -14.86% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.70 | 0.77 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -0.45% | -0.81% | -26.13% | -42.33% |
| Safety | ||||
| Net Debt / EBITDA | 2.58 | 2.82 | 4.01 | 6.65 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |